Evidence map›Paper›PMID 37185743›Full record

ArticleCurrent issues in molecular biology2023

Specific Targeting and Labeling of Colonic Polyps in

Michael A Turner, Kristin E Cox, Shanglei Liu, Nicholas Neel, Siamak Amirfakhri, Hiroto Nishino, Mojgan Hosseini, Joshua A Alcantara, Amer Ali Abd El-Hafeez, Thinzar M Lwin and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current issues in molecular biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 1 country.

Michael A TurnerDivision of Surgical Oncology, Department of Surgery, University of California San Diego, La Jolla, CA 92037, USA.ORCID 0000-0001-8949-3136
Kristin E CoxDivision of Surgical Oncology, Department of Surgery, University of California San Diego, La Jolla, CA 92037, USA.ORCID 0000-0001-8621-1869
Shanglei LiuDivision of Surgical Oncology, Department of Surgery, University of California San Diego, La Jolla, CA 92037, USA.ORCID 0000-0001-8723-6507
Nicholas NeelDivision of Surgical Oncology, Department of Surgery, University of California San Diego, La Jolla, CA 92037, USA.
Siamak AmirfakhriDivision of Surgical Oncology, Department of Surgery, University of California San Diego, La Jolla, CA 92037, USA.
Hiroto NishinoDivision of Surgical Oncology, Department of Surgery, University of California San Diego, La Jolla, CA 92037, USA.
Mojgan HosseiniDepartment of Pathology, University of California San Diego, La Jolla, CA 92037, USA.
Joshua A AlcantaraDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA 92037, USA.
Amer Ali Abd El-HafeezDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA 92037, USA.
Thinzar M LwinDepartment of Surgical Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA.ORCID 0000-0003-1820-088X
Kavita MallyaDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA.ORCID 0000-0001-6562-5827
Joseph R PisegnaDepartment of Gastroenterology, VA Los Angeles Healthcare System, Los Angeles, CA 90073, USA.
Satish K SinghMedical Service, Section of Gastroenterology, VA Boston Healthcare System, Boston, MA 02130, USA.ORCID 0000-0002-7664-3155
Pradipta GhoshDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA 92037, USA.
Robert M HoffmanDivision of Surgical Oncology, Department of Surgery, University of California San Diego, La Jolla, CA 92037, USA.
Surinder K BatraDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA.ORCID 0000-0001-9470-9317
Michael BouvetDivision of Surgical Oncology, Department of Surgery, University of California San Diego, La Jolla, CA 92037, USA.ORCID 0000-0002-0086-2159
University of California San Diego · USUniversity of Nebraska Medical Center · USBoston University · USCity Of Hope National Medical Center · USVA Greater Los Angeles Healthcare System · US

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9M
UCSD Cancer Center Training Program in Drug DevelopmentT32CA121938 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael Bouvet, Dwayne G. Stupack · 2006 to 2026
$10.3M
Network-Based Novel Therapeutics in Colorectal CancersUG3TR002968 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DAS, SOUMITA, GHOSH, PRADIPTA · 2019 to 2021
$946k
Network-Based Novel Therapeutics in Colorectal CancersUH3TR002968 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DAS, SOUMITA, GHOSH, PRADIPTA · 2022 to 2022
$356k
Development of Near Infrared Fluorescence-Guided Surgical Navigation and Tumor Specific Photoimmunotherapy for Improved Outcomes for GI CancersI01BX003856 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI BOUVET, MICHAEL · 2018 to 2022
–
Optical Spectroscopy in the Management of Colorectal NeoplasiaI01CX001146 · VA · VA BOSTON HEALTH CARE SYSTEM · PI SINGH, SATISH K · 2015 to 2023
–
CMA: Marker-assisted prevention and risk stratification (MAPRS): Artificial Intelligence Endoscopy for Colorectal Cancer Prevention (CMA1)I01BX004455 · VA · VA BOSTON HEALTH CARE SYSTEM · PI SINGH, SATISH K · 2019 to 2022
–
CMA- Marker-assisted prevention and risk stratification (MAPRS): Mucin signatures and molecular imaging for the early detection of colorectal cancer.I01BX004494 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI BOUVET, MICHAEL · 2020 to 2023
–
CMA: Cancer Stem Cells in the Pathogenesis and Treatment of Colorectal CancerI01BX004560 · VA · VA GREATER LOS ANGELES HEALTHCARE SYSTEM · PI PISEGNA, JOSEPH R · 2019 to 2022
–
BLRD VA I01 BX003856BLRD VA I01 BX004455BLRD VA I01 BX004494BLRD VA I01 BX004560CSRD VA I01 CX001146NCATS NIH HHS UG3 TR002968NCATS NIH HHS UH3 TR002968NCI NIH HHS P30 CA023100NCI NIH HHS T32 CA121938NIH HHS T32CA121938
6 · The paper itself

Abstract

Poor visualization of polyps can limit colorectal cancer screening. Fluorescent antibodies to mucin5AC (MUC5AC), a glycoprotein upregulated in adenomas and colorectal cancer, could improve screening colonoscopy polyp detection rate. Adenomatous polyposis coli flox mice with a

Indexed as

colorectal cancerdetectionfluorescencefluorescence labelinggenetically engineered mouse modelsmucinpolyps

Identifiers

PMID37185743
PMCPMC10136452
OpenAlexW4364366044

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.